Swell

Pharming Group and Salix Pharmaceuticals have introduced Ruconest (C1 esterase inhibitor [recombinant]) 50IU/kg in the US, a treatment developed to treat acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).

Ruconest can be administered by the patient after receiving training by a healthcare provider.

According to Pharming, efficacy of Ruconest in clinical studies was not established in HAE patients with laryngeal attacks.

Salix Pharmaceuticals CEO Carolyn Logan said: “We’re excited to offer the only recombinant C1 esterase inhibitor therapy for HAE in the US.

“Ruconest treats the root cause of HAE attacks, which has been shown to raise C1 inhibitor levels to within the normal range.

Ruconest can be self-administered by appropriately trained patients and is effective at stopping most HAE attacks in one dose.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Ruconest can be administered by the patient after receiving training by a healthcare provider.”

The drug has been introduced following US Food and Drug Administration (FDA) approval in July.

Pharming produces Ruconest in the Netherlands, while Salix received exclusive rights from Pharming to commercialise the drug in North America, and market it for the treatment of acute HAE attack symptoms.

Pharming CEO Sijmen de Vries said: “Ruconest helped patients in other countries around the world and we look forward to seeing the difference it will make in the lives of HAE patients in the US.”

HAE is a rare genetic condition, which affects one in 10,000 and one in 50,000 people, and it results in episodes of swelling in different parts of the body, including the hands, feet, abdomen and face.


Image: Swollen right hand in a female patient during a hereditary angioedema attack. Photo: courtesy of LucyHAE.